@article{3104757,
    title = "Stem cells in ductal breast cancer: Immunohistochemical expression of CD44, CD24, CD133, and ALDH-1 markers in 104 cases",
    author = "Korfias, D. and Contis, J. and Frangou-Plemenou, M. and Gennatas, K. and Kondis, A. and Vlachodimitropoulos, D.",
    journal = "European Journal of Gynaecological Oncology",
    year = "2020",
    volume = "41",
    number = "1",
    pages = "36-41",
    publisher = "IMR Press Limited",
    issn = "0392-2936",
    doi = "10.31083/j.ejgo.2020.01.4810",
    keywords = "aldehyde dehydrogenase isoenzyme 1;  CD133 antigen;  CD24 antigen;  epidermal growth factor receptor 2;  Hermes antigen, adult;  aged;  Article;  breast carcinoma;  cancer size;  cancer stem cell;  cell membrane;  cell proliferation;  human;  human cell;  immunohistochemistry;  major clinical study;  triple negative breast cancer;  tumor differentiation",
    abstract = "Objective: The aim of this study was to evaluate the immunohistochemical expression of stem cell markers CD44, CD24, CD133, and ALDH-1 in breast carcinomas and investigate any correlation with stage, degree of tumor differentiation, cell proliferation index, and hormone receptors status. Materials and Methods: One hundred and four cases of invasive ductal breast carcinomas were studied and classified according to grade and stage, hormonal status, and C-erbB2 expression. A semi-automatic Ventana method was used to examine by semi-quantitative method the immunohistochemical expression of anti-CD133, CD24, CD44, and ALDH1 antibodies. Results: CD44, CD24, and ALDH1 markers demonstrated a statistically significant correlation with higher disease stage and triple negative cancers (94%-55.5%). CD133 correlated with triple negative cancers (55.5%). No correlation with other clinical data or tumor differentiation was observed. Conclusion: Triple negative breast cancers express specific stem cell markers responsible for cell/stroma interaction and this is a useful tool in predicting tumor progression and developing specific targeted therapies. © 2020 S.O.G. CANADA Inc.. All rights reserved."
}